WO2023108401A1 - Vecteur recombiné, son procédé de construction et son application - Google Patents

Vecteur recombiné, son procédé de construction et son application Download PDF

Info

Publication number
WO2023108401A1
WO2023108401A1 PCT/CN2021/137780 CN2021137780W WO2023108401A1 WO 2023108401 A1 WO2023108401 A1 WO 2023108401A1 CN 2021137780 W CN2021137780 W CN 2021137780W WO 2023108401 A1 WO2023108401 A1 WO 2023108401A1
Authority
WO
WIPO (PCT)
Prior art keywords
sgrna
plasmid
recombinant vector
backbone
neurotensin
Prior art date
Application number
PCT/CN2021/137780
Other languages
English (en)
Chinese (zh)
Inventor
朱英杰
陈子君
徐薇
Original Assignee
深圳先进技术研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳先进技术研究院 filed Critical 深圳先进技术研究院
Priority to PCT/CN2021/137780 priority Critical patent/WO2023108401A1/fr
Publication of WO2023108401A1 publication Critical patent/WO2023108401A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts

Definitions

  • the invention relates to the field of biotechnology, in particular to a recombinant vector and its construction method and application.
  • optogenetics is mainly used to activate specific cells, which has the following limitations: 1Invasive. Optogenetics requires embedding a fiber optic ceramic ferrule and is an invasive procedure. 2Limitation of the scope of activities. If wired optogenetic activation is used, it is necessary to link the optical fiber to the ceramic ferrule, which will limit the range of activity of the mouse; if wireless optogenetic activation is used, a magnetic field needs to be arranged with a coil. In order to ensure the strength of the magnetic field, the mouse can move as little as possible. The scope is also limited. 3 Photothermal effect on cell damage.
  • Optogenetic stimulation usually uses blue light, which has a strong photothermal effect, and if it is activated for a long time or multiple times, it may cause damage to the neurons at the tip of the optical fiber. 4Limitations of applicable scenarios. Due to the limitations of the range of motion mentioned in 2 and 3 above and the damage to cells caused by the photothermal effect, this technology is applicable to limited scenarios. When it is necessary to manipulate specific neurons in mice for a long time or in a complex environment, this technology is not suitable. apply again.
  • a method for constructing a recombinant vector comprising the steps of:
  • a sgRNA fragment is inserted into the sgRNA backbone plasmid with chemical genetics activation elements, and the sgRNA fragment is used to knock out the neurotensin protein to obtain the recombinant vector.
  • the construction method of the above recombinant vector combines CRISPR gene editing technology and chemical genetic activation technology to obtain a recombinant vector that can be used to knock out the neurotensin protein of neurotensin-positive neurons, and activate the neurotensin-positive neurons that can knock out neurotensin protein through chemical genetics , which is convenient for long-term activation of specific neurons, and achieves the purpose of long-term activation of neurotensin-positive neurons knocking out neurotensin.
  • Chemogenetic activation technology is only through injection or oral administration of corresponding activation drugs without invasive surgery.
  • the step of constructing the sgRNA backbone plasmid with chemical genetics activation elements comprises:
  • Plasmid recombination of the original sgRNA backbone plasmid with a chemical genetics plasmid carrying the chemical genetics activation element is carried out using a plasmid recombination technique.
  • the step of constructing the sgRNA backbone plasmid with chemical genetics activation elements comprises:
  • the fragment containing the sgRNA backbone and the fragment containing the chemogenetic activation element are connected to obtain the sgRNA backbone plasmid with the chemogenetic activation element.
  • the original sgRNA backbone plasmid includes AAV-U6-sgRNA(backbone)-pCBh-DIO-ChR2-mCherry plasmid;
  • the chemical genetics plasmid includes pAAV-hSyn-DIO-hM3D(Gq)- mCherry plasmid;
  • the steps of carrying out plasmid recombination of the original sgRNA backbone plasmid and the chemical genetics plasmid include:
  • the fragment containing AAV-U6-sgRNA (backbone) and the fragment containing DIO-hM3D(Gq)-mCherry were ligated.
  • the step of inserting the sgRNA fragment into the sgRNA backbone plasmid with chemical genetic activation elements comprises: using plasmid recombination technology to insert the sgRNA fragment into the sgRNA backbone plasmid with chemical genetic activation elements Insert the sgRNA fragment.
  • the recombinant vector is a viral vector
  • the following step is further included: inserting the sgRNA Fragments of recombinant plasmids are packaged into viruses.
  • the sequence of the sgRNA fragment is as shown in SEQ ID No.1.
  • a recombinant vector which is constructed by the method for constructing the above-mentioned recombinant vector.
  • a recombinant vector comprising: a sgRNA backbone plasmid with a chemical genetic activation element, an sgRNA fragment is inserted into the sgRNA backbone plasmid with a chemical genetic activation element, and the sgRNA fragment is used to knock out neurotensin protein.
  • the chemogenetic activation element is a chemogenetic excitatory receptor.
  • the sequence of the sgRNA fragment is as shown in SEQ ID No.1.
  • the recombinant vector is a viral vector.
  • the reagent further includes an activator for activating the chemogenetic activation element.
  • a method for activating neurotensin-positive neurons comprising the steps of:
  • the above-mentioned recombinant vector is packaged into a virus and injected into the brain area of an animal model for expression, and then an activator is injected into the animal model, the animal model can express CRISPR nuclease, and the activator is used to activate the chemical genetic activation element.
  • Fig. 1 is AAV-U6-sgRNA(backbone)-pCBh-DIO-ChR2-mCherry plasmid map
  • Fig. 2 is pAAV-hSyn-DIO-hM3D(Gq)-mCherry plasmid map
  • Fig. 3 is the enzyme digestion verification map of AAV-U6-sgRNA(backbone)-pCBh-DIO-hM3D(Gq)-mCherry plasmid;
  • Figure 4 is a sequencing verification map of the AAV-U6-sgRNA(backbone)-pCBh-DIO-hM3D(Gq)-mCherry plasmid;
  • Figure 5 is a sequence verification map of sAAV-U6-sgRNA(Nts)-pCBh-DIO-hM3D(Gq)-mCherry plasmid;
  • Fig. 6 is the c-fos immunofluorescence staining figure of embodiment 2;
  • Fig. 7 is a graph comparing the feeding behavior of the experimental mice and control mice in Example 3.
  • One embodiment of the present application provides a method for constructing a recombinant vector.
  • the construction method combines CRISPR gene editing technology and chemical genetic activation technology to obtain a recombinant vector that can be used to knock out the neurotensin protein of neurotensin-positive neurons, and through chemical genetics Chemical activation of neurotensin-positive neurons knocked out of neurotensin protein is convenient for long-term activation of specific neurons to achieve the purpose of long-term activation of neurotensin-positive neurons knocked out of neurotensin protein.
  • Chemogenetic activation technology is only through injection or oral administration
  • the activating drug does not require invasive surgery, is non-invasive, improves the adaptability of animals, and no longer needs to give light stimulation through optical fiber connection to LED, reduces the use of experimental equipment during the experiment, improves convenience, and does not It needs to be connected with an optical fiber or move in a specific range of magnetic field, so the range of activities of the mouse is wider; it avoids the cell damage caused by the photothermal effect, can activate specific neurons for a long time, and has a wider range of applications.
  • neurotensin (abbreviated as NT or Nts) is neurotensin, also known as neurotensin, which is named after its obvious antihypertensive effect and exists in nerve tissue. Due to its specific vascular effect and blood pressure lowering effect, Easy to separate from other peptide hormones. NT-secreting cells were first discovered in the hypothalamus, and later confirmed to be secreted by N cells in the distal jejunum and ileal mucosa, accounting for 80% to 90% of the total NT in the body. N cells are most distributed in the ileum mucosa, followed by the jejunum, while only a small amount exists in the stomach, duodenum, gallbladder, and pancreas.
  • the method for constructing the above-mentioned recombinant vector includes the following steps S110-S120:
  • the step of constructing the sgRNA backbone plasmid with the chemical genetics activation element comprises: performing plasmid recombination of the original sgRNA backbone plasmid and the chemical genetics plasmid with the chemical genetics activation element using plasmid recombination technology.
  • Chemical genetics technology also known as DREADDs (designer receptors exclusively activated by designer drugs, receptors activated only by specific drugs) technology, is a chemical genetics platform modified based on G protein-coupled receptors. Different G protein-coupled receptors are modified so that they can transmit artificially synthesized proteins. The modified receptors can only be activated or inhibited by artificially synthesized special compounds, and activate the corresponding GPCR signaling pathways, thereby triggering different cellular processes. changes in excitability. This technology is widely used to enhance or inhibit the activity of neurons in a cell-specific and non-invasive manner. Although chemical genetics lacks the precise time control ability like optogenetics, since long-term neuronal circuit regulation is most likely to be needed in long-term behavioral research or disease treatment, this technology will be very suitable for this class application.
  • Chemogenetic activation elements are used to activate neurotensin-positive neurons.
  • the chemogenetic activation element is a chemogenetic excitatory receptor.
  • Chemogenetic excitatory receptors include, for example, hM1Dq, hM3Dq, hM5Dq, and the like.
  • steps of S110 include S111-S113:
  • the original sgRNA backbone plasmid is the AAV-U6-sgRNA(backbone)-pCBh-DIO-ChR2-mCherry plasmid. It should be noted that the original sgRNA backbone plasmid is not limited to the AAV-U6-sgRNA(backbone)-pCBh-DIO-ChR2-mCherry plasmid, and can also be other sgRNA backbone plasmids, which can be selected according to needs.
  • the step of digesting the original sgRNA backbone plasmid to obtain a fragment containing the sgRNA backbone includes: digesting the AAV-U6-sgRNA(backbone)-pCBh-DIO-ChR2-mCherry plasmid to obtain a fragment containing AAV-U6- Fragments of sgRNA (backbone).
  • the restriction endonuclease of Asc I and Nhe I-HF restriction endonuclease carries out double digestion.
  • Digestion system 1 ⁇ g of plasmid, 5 ⁇ L of 5x Cutsmart buffer solution, 1 ⁇ L of Asc I endonuclease, 1 ⁇ L of Nhe I-HF endonuclease, and supplement the whole system to 50 ⁇ L with deionized water. Digestion conditions: 37°C, incubate for 3 hours.
  • the chemogenetics plasmid is the pAAV-hSyn-DIO-hM3D(Gq)-mCherry plasmid.
  • the chemical genetics plasmid is not limited to the pAAV-hSyn-DIO-hM3D(Gq)-mCherry plasmid, and can also be other chemical genetics plasmids with chemical genetics activation elements, which can be selected according to needs.
  • the step of digesting the chemical genetics plasmid to obtain a fragment containing the chemical genetics activation element includes: digesting the pAAV-hSyn-DIO-hM3D(Gq)-mCherry plasmid to obtain a fragment containing DIO-hM3D(Gq) ) - fragment of mCherry.
  • the restriction endonuclease of Asc I and Nhe I-HF restriction endonuclease carries out double digestion.
  • Digestion system 1 ⁇ g of plasmid, 5 ⁇ L of 5x Cutsmart buffer solution, 1 ⁇ L of Asc I endonuclease, 1 ⁇ L of Nhe I-HF endonuclease, and supplement the whole system to 50 ⁇ L with deionized water. Digestion conditions: 37°C, incubate for 3 hours.
  • sequence of S111 and S112 is not limited, S111 may be performed first and then S112 may be performed, S112 may be performed first and then S111 may be performed, or S111 and S112 may be performed simultaneously.
  • S113 Ligate the fragment containing the sgRNA backbone with the fragment containing the chemogenetic activation element to obtain the sgRNA backbone plasmid with the chemogenetic activation element.
  • the step of linking the fragment containing the sgRNA backbone and the fragment containing the chemogenetic activation element comprises: linking the fragment comprising AAV-U6-sgRNA (backbone) and the fragment comprising DIO-hM3D(Gq)-mCherry .
  • the following system was used for fragment ligation: 1 ⁇ L of fragments containing AAV-U6-sgRNA (backbone), 1 ⁇ L of fragments containing DIO-hM3D(Gq)-mCherry, 5 ⁇ L of T4 buffer solution, 1 ⁇ L of T4 ligase, Supplement the whole system to 10 ⁇ L with deionized water, and let stand at room temperature for 30 minutes.
  • the step of ligating the fragment containing the sgRNA backbone and the fragment containing the chemogenetic activation element it further includes: a step of amplifying and screening the recombinant backbone plasmid obtained by ligating the above two fragments .
  • the step of amplifying the recombinant backbone plasmid includes: transferring the above ligation system into competent cells for amplifying and culturing. Specifically, 20 ⁇ L of competent cells were added to the above ligation system, allowed to stand on ice for 30 minutes, then heat-shocked at 42°C for 45 seconds, then left to stand on ice for 3 minutes, and then 600 ⁇ L of liquid medium without ampicillin was added, 37 ° C, cultured on a shaker at 220 rpm. After 30-40 minutes, centrifuge at 3500 x g for 4 minutes, suck off the supernatant, and leave about 100 ⁇ L of liquid.
  • Verification methods include enzyme digestion verification and sequencing verification.
  • sequencing verification includes: designing multiple sequencing sites, sending them to a sequencing company for sequencing, and then performing sequence comparison.
  • the primer sequences of the designed sequencing sites are shown in SEQ ID No.2-SEQ ID No.5.
  • sequence shown in SEQ ID No.2 is: 5'-CATAGCGTAAAAGGAGCAACA-3' (ie Primer 1).
  • SEQ ID No.3 The sequence shown in SEQ ID No.3 is: 5'-TCTTTCTTCTGCATTACGGGG-3' (i.e. Primer 2).
  • sequence shown in SEQ ID No.4 is: 5'-GGGAAACGCCTGGTATCTTT-3' (ie Primer 3).
  • sequence shown in SEQ ID No.5 is: 5'-CAGCACAAAAGGAAACTCACC-3' (ie Primer 4).
  • plasmid recombination technology is used to insert sgRNA fragments into sgRNA backbone plasmids with chemical genetic activation elements.
  • sequence of the sgRNA fragment is shown in SEQ ID No.1. Specifically, the sequence shown in SEQ ID No.1 is: 5'-TAACGTGAACAGCCCGGCCG-3'.
  • sequence of the sgRNA fragment is not limited to the sequence shown in SEQ ID No.1, and can also be other sgRNA fragments that knock out the neurotensin protein.
  • the recombinant vector is a viral vector
  • the following step is further included: packaging the recombinant plasmid with the sgRNA fragment inserted into Virus.
  • the virus may be, for example, AVV virus (adenovirus). It should be noted that the virus is not limited to the AVV virus, and may be other viruses, which can be selected according to needs.
  • An embodiment of the present application also provides a recombinant vector, which is constructed by the method for constructing a recombinant vector described above. Relevant specific descriptions can be found above, and will not be repeated here.
  • the recombinant vector includes: sgRNA backbone plasmid with chemical genetics activation element, chemical genetics activation element is used to activate neurotensin positive neurons, sgRNA fragment is also inserted in the sgRNA backbone plasmid with chemical genetics activation element, sgRNA Fragments are used to knock out neurotensin protein.
  • the chemogenetic activation element is a chemogenetic excitatory receptor. See the above for detailed description, and will not repeat them here.
  • sequence of the sgRNA fragment is shown in SEQ ID No.1. See the above for detailed description, and will not repeat them here.
  • the recombinant vector is a viral vector. See the above for detailed description, and will not repeat them here.
  • One embodiment of the present application also provides the application of the above-mentioned recombinant vector in the preparation of reagents.
  • the reagent is used to knock out the neurotensin protein of neurotensin-positive neurons.
  • the reagent is used to activate neurotensin positive neurons.
  • the reagent is used for knocking out neurotensin protein of neurotensin-positive neurons, and activating neurotensin-positive neurons knocked out of neurotensin protein.
  • the reagent further includes an activator, and the activator is used to activate the chemogenetic activation element.
  • Activators activate elements through chemical genetics and activate corresponding GPCR signaling pathways, thereby triggering different excitatory changes in cells.
  • the activator can activate the neurotensin-positive neuron knocked out of the neurotensin protein by activating the chemogenetic activation element.
  • the activator is CNO (clozapine nitric oxide, clozapine N-oxide). It should be noted that the activator is not limited to CNO, and may be other activators, and an activator capable of activating the chemogenetic activating element can be selected as required.
  • One embodiment of the present application also provides a method for activating neurotensin-positive neurons, comprising the following steps:
  • the above-mentioned recombinant vector is packaged into a virus and injected into the brain area of the animal model for expression, and then injected into the animal model with an activator, the animal model can express CRISPR nuclease, and the activator is used to activate the chemical genetic activation element.
  • Activators activate elements through chemical genetics and activate corresponding GPCR signaling pathways, thereby triggering different excitatory changes in cells.
  • the activator can activate the neurotensin-positive neuron knocked out of the neurotensin protein by activating the chemogenetic activation element.
  • the activator is CNO (clozapine nitric oxide, clozapine N-oxide). It should be noted that the activator is not limited to CNO, and may be other activators, and an activator capable of activating the chemogenetic activating element can be selected as required.
  • the CRISPR nuclease is Cas9 nuclease. It should be noted that the CRISPR nuclease is not limited to Cas9 nuclease, and other CRISPR nucleases can also be selected according to needs.
  • the animal model is LSL-Cas9 and Nts-ires-Cre double transfected mice. It should be noted that the animal model is not limited to the mouse mentioned above, and other animal models can be selected as needed.
  • the method for activating neurotensin-positive neurons comprises: injecting sAAV-U6-sgRNA(Nts)-pCBh-DIO-hM3D(Gq )-mCherry virus, three weeks later, the virus was fully expressed. At this moment, the Nts protein in Nts-positive cells was knocked out, and when CNO (clozapine nitric oxide, clozapine N-oxide) was injected 30 minutes later, the Nts-positive neurons knocked out of Nts were activated.
  • the specific brain region may be, for example, the lateral septum (LS). It should be noted that the specific brain region is not limited to the lateral septal nucleus, and may also be a brain region of other neurons, which is only used for illustration and not limitation.
  • CRISPR/Cas9 Clustered Regularly Interspersed Short Palindromic Repeats gene editing technology: CRISPR/Cas9 is an adaptive immune defense formed during the long-term evolution of bacteria and archaea, which can be used to fight against invading viruses and foreign DNA.
  • CRISPR/Cas9 is an adaptive immune defense formed during the long-term evolution of bacteria and archaea, which can be used to fight against invading viruses and foreign DNA.
  • researchers published several articles introducing a new method for gene knockout in cell lines based on CRISPR-Cas9 technology (Wang et.al., Science, 2013; Ophir Shalem et.al.Science, 2013).
  • the CRISPR-Cas9 system consists of two parts, one is the sgRNA (small guide RNA) sequence with a length of about 20 bp, which is used to identify the target genome, and the other is the double-stranded DNA nuclease—Cas9, which exists near the CRISPR site.
  • sgRNA small guide RNA
  • the target site is cut, and finally the broken DNA is repaired through the intracellular non-homologous end joining mechanism and homologous recombination repair mechanism, thereby forming gene knockout and insertion, and finally realizing gene (directed) editing.
  • This technology was quickly applied to the construction of gene knockout mice and rat animal models.
  • Chemical genetics technology also known as DREADDs (designer receptors exclusively activated by designer drugs, receptors activated only by specific drugs) technology, is a chemical genetics platform modified based on G protein-coupled receptors. Different G protein-coupled receptors are modified so that they can transmit artificially synthesized proteins. The modified receptors can only be activated or inhibited by artificially synthesized special compounds, and activate the corresponding GPCR signaling pathways, thereby triggering different cellular processes. changes in excitability. This technique is widely used to enhance or inhibit neuronal activity in a cell-specific, non-invasive manner.
  • the reagents and instruments used in the examples are all conventional choices in the art unless otherwise specified.
  • the experimental methods without specific conditions indicated in the examples are usually implemented according to conventional conditions, such as the conditions described in literature, books or the method recommended by the kit manufacturer.
  • the reagents used in the examples are all commercially available.
  • Embodiment 1 Construction of sAAV-U6-sgRNA(Nts)-pCBh-DIO-hM3D(Gq)-mCherry virus
  • the AAV-U6-sgRNA(backbone)-pCBh-DIO-ChR2-mCherry plasmid was obtained from Stanford University, and the pAAV-hSyn-DIO-hM3D(Gq)-mCherry plasmid (Cat. No.: 44361) was purchased from Addgene (a plasmid ordering company).
  • the plasmid map of AAV-U6-sgRNA(backbone)-pCBh-DIO-ChR2-mCherry is shown in Figure 1.
  • the plasmid map of pAAV-hSyn-DIO-hM3D(Gq)-mCherry is shown in FIG. 2 .
  • 1AAV-U6-sgRNA(backbone)-pCBh-DIO-ChR2-mCherry plasmid was digested to obtain a fragment containing AAV-U6-sgRNA(backbone), represented by fragment A.
  • the following system was used for fragment ligation: 1 ⁇ L of A fragment, 1 ⁇ L of B fragment, 5 ⁇ L of T4 buffer solution, 1 ⁇ L of T4 ligase, supplemented the whole system to 10 ⁇ L with deionized water, and stood at room temperature for 30 minutes.
  • Figure 3 is a diagram of restriction enzyme digestion verification of AAV-U6-sgRNA(backbone)-pCBh-DIO-hM3D(Gq)-mCherry plasmid. It can be seen from Figure 3 that 3 single clone colonies were picked and amplified, among which No. 2 and No. 3 were the correct plasmids.
  • Figure 4 is a sequence verification map of the AAV-U6-sgRNA(backbone)-pCBh-DIO-hM3D(Gq)-mCherry plasmid. It can be seen from Figure 4 that the constructed plasmid is correct.
  • the designed sequencing sites are as follows:
  • Primer 1 5'-CATAGCGTAAAAGGAGCAACA-3';
  • Primer 2 5'-TCTTTCTTCTGCATTACGGGG-3';
  • Primer 3 5'-GGGAAACGCCTGGTATCTTT-3';
  • Primer 4 5'-CAGCACAAAAGGAAACTCACC-3'.
  • Insert the sgRNA sequence into the modified backbone plasmid Using plasmid recombination construction technology, insert the synthesized sgRNA sequence into the backbone plasmid (ie AAV-U6-sgRNA(backbone)-pCBh-DIO -hM3D(Gq)-mCherry plasmid), the sAAV-U6-sgRNA(Nts)-pCBh-DIO-hM3D(Gq)-mCherry plasmid was obtained.
  • the confirmed sAAV-U6-sgRNA(Nts)-pCBh-DIO-hM3D(Gq)-mCherry plasmid was packaged into the corresponding AAV virus to obtain sAAV-U6-sgRNA(Nts)-pCBh-DIO-hM3D(Gq)- mCherry virus.
  • Example 2 Immunofluorescence staining of c-fos (early instant gene, which indicates that cells are activated) to prove that specific cells are activated by chemogenetics
  • mice The sAAV-U6-sgRNA(Nts)-pCBh-DIO-hM3D(Gq)-mCherry virus was injected into LSL-Cas9 (#024857) and Nts-ires-Cre (#017525) double transfected mice (commercially available mice , were introduced from Jackson lab) lateral septum (Lateral septum, LS). After three weeks, the virus was fully expressed. After intraperitoneal injection of 2 mg/kg of CNO (clozapine nitric oxide, clozapine N-oxide), 3 minutes later, the mice were perfused and brains were taken, followed by c-fos immunofluorescence staining.
  • CNO clozapine nitric oxide, clozapine N-oxide
  • FIG. 6 is a c-fos immunofluorescent staining image of Example 2.
  • the sAAV-U6-sgRNA(Nts)-pCBh-DIO-hM3D(Gq)-mCherry virus and the control virus sAAV-U6-sgRNA(LacZ)-pCBh-DIO-hM3D(Gq)-mCherry were injected on LSL-Cas9 (# 024857) and Nts-ires-Cre (#017525) double-transformed mice (commercially available mice, both imported from Jackson lab) lateral septum (LS). After three weeks, the virus was fully expressed.
  • Fig. 7 is a graph comparing the feeding behavior of the experimental mice and control mice in Example 3.
  • mice i.e. injected with sAAV-U6-sgRNA(LacZ)-pCBh-DIO-hM3D(Gq)-mCherry virus
  • the food intake of mice decreased significantly; for experimental mice (that is, injected with sAAV-U6-sgRNA(Nts)-pCBh-DIO-hM3D(Gq)-mCherry virus), activation of the mouse lateral septum has knocked out the Nts protein Nts-positive neurons, food intake of mice did not differ significantly.
  • Nts protein in the Nts-positive neurons in the lateral septum of the mouse has an important function in the feeding behavior, and also shows that the method of the present application has indeed knocked out the Nts-positive neurons in the lateral septum of the mouse.
  • Nts protein in Yuan shows that after activating neurotensin-positive neurons in specific brain regions to knock out neurotensin, it no longer affects feeding behavior.
  • the method of the present application combines CRISPR gene editing technology and chemical genetic activation technology to knock out the neurotensin protein of neurotensin-positive neurons, and activate the neurotensin-positive neurons that knock out neurotensin protein through chemical genetics. Neurons are activated for a long time to achieve the purpose of long-term activation of neurotensin-positive neurons that knock out neurotensin.
  • the chemical genetics activation technology is only through injection or oral administration of corresponding activation drugs without invasive surgery.
  • the mouse has a wider range of activities; it avoids the cell damage caused by the photothermal effect, and can activate specific neurons for a long time, and has a wider range of applications.

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne un vecteur recombiné, son procédé de construction et son application. Le procédé de construction d'un vecteur recombiné comprend les étapes suivantes : construction de plasmides à chaîne principale d'ARNsg possédant des éléments chimiques d'activation génétique ; et insertion de fragments d'ARNsg dans les plasmides à chaîne principale d'ARNsg possédant des éléments chimiques d'activation génétique, les fragments d'ARNsg étant utilisés pour neutraliser les protéines de la neurotensine afin d'obtenir un vecteur recombiné. Selon le procédé de construction d'un vecteur recombiné, une technologie d'édition génétique CRISPR et une technologie d'activation génétique chimique sont combinées pour obtenir un vecteur recombiné pouvant être utilisé pour inactiver les protéines de la neurotensine des neurones positifs à la neurotensine, et en activant génétiquement par voie chimique les neurones positifs à la neurotensine dont les protéines de la neurotensine sont inactivées, le but de l'activation à long terme des neurones positifs à la neurotensine dont les protéines de la neurotensine sont inactivées est atteint.
PCT/CN2021/137780 2021-12-14 2021-12-14 Vecteur recombiné, son procédé de construction et son application WO2023108401A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2021/137780 WO2023108401A1 (fr) 2021-12-14 2021-12-14 Vecteur recombiné, son procédé de construction et son application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2021/137780 WO2023108401A1 (fr) 2021-12-14 2021-12-14 Vecteur recombiné, son procédé de construction et son application

Publications (1)

Publication Number Publication Date
WO2023108401A1 true WO2023108401A1 (fr) 2023-06-22

Family

ID=86774979

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/137780 WO2023108401A1 (fr) 2021-12-14 2021-12-14 Vecteur recombiné, son procédé de construction et son application

Country Status (1)

Country Link
WO (1) WO2023108401A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106163569A (zh) * 2014-01-20 2016-11-23 维克塔-霍洛斯公司 活化的神经降压素分子及其用途
US20180078658A1 (en) * 2015-03-31 2018-03-22 New York University Compositions and method for reducing seizures
CN109069673A (zh) * 2016-03-09 2018-12-21 F·阿瑟夫 使用dreadd用于治疗神经元疾病中的神经元调节
WO2020163102A1 (fr) * 2019-02-05 2020-08-13 The Broad Institute, Inc. Agents thérapeutiques interneurones spécifiques permettant de normaliser l'excitabilité des cellules neuronales et de traiter le syndrome de dravet

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106163569A (zh) * 2014-01-20 2016-11-23 维克塔-霍洛斯公司 活化的神经降压素分子及其用途
US20180078658A1 (en) * 2015-03-31 2018-03-22 New York University Compositions and method for reducing seizures
CN109069673A (zh) * 2016-03-09 2018-12-21 F·阿瑟夫 使用dreadd用于治疗神经元疾病中的神经元调节
WO2020163102A1 (fr) * 2019-02-05 2020-08-13 The Broad Institute, Inc. Agents thérapeutiques interneurones spécifiques permettant de normaliser l'excitabilité des cellules neuronales et de traiter le syndrome de dravet

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PEREZ-BONILLA PATRICIA, SANTIAGO-COLON KRYSTAL, MATASOVSKY JILLIAN, RAMIREZ-VIRELLA JARIEL, KHAN RABAIL, GARVER HANNAH, FINK GREGO: "Activation of ventral tegmental area neurotensin Receptor-1 neurons promotes weight loss", NEUROPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 195, 1 September 2021 (2021-09-01), AMSTERDAM, NL, pages 108639, XP093073170, ISSN: 0028-3908, DOI: 10.1016/j.neuropharm.2021.108639 *
YAN, XI ET AL.: "Exploration and Prospects of Chemogenetics in Treatment of Epilepsy", JOURNAL OF CLINICAL NEUROSURGERY, vol. 18, no. 2, 15 April 2021 (2021-04-15), ISSN: 1672-7770 *

Similar Documents

Publication Publication Date Title
JP7460178B2 (ja) ＣＲＩＳＰＲ－Ｃａｓ１２ｊ酵素およびシステム
CN113271955A (zh) 用于细胞介导的溶瘤病毒疗法的增强的系统
CN107326046A (zh) 一种提高外源基因同源重组效率的方法
WO2019214604A1 (fr) Protéine effectrice crispr/cas et système associé
CN107109434A (zh) 新颖cho整合位点和其用途
CN110484549B (zh) 基因组靶向修饰方法
CN111875709B (zh) 一种融合蛋白及其在构建筛选冠状病毒3cl蛋白酶抑制剂的系统中的应用
CN108130342A (zh) 基于Cpf1的植物基因组定点编辑方法
CN106062199A (zh) 制造腺病毒和相应质粒的方法
CN111575319B (zh) 一种高效的crispr rnp和供体dna共位介导的基因插入或替换方法及其应用
WO2019206233A1 (fr) Protéine effectrice crispr/cas éditée par arn et système
CN110760511B (zh) 一种用于治疗杜氏肌营养不良症的gRNA、表达载体、CRISPR-Cas9系统
CN116239703A (zh) 一种融合蛋白及含有其的高效特异碱基编辑系统和应用
WO2020087631A1 (fr) Système et procédé d'édition génomique basée sur des nucléases c2c1
CN106754949A (zh) 猪肌抑素基因编辑位点864‑883及其应用
WO2023108401A1 (fr) Vecteur recombiné, son procédé de construction et son application
JPS62248491A (ja) 遺伝子伝達動物において外来遺伝子を自律状態に遺伝的に保持するためのベクタ−内で利用可能なｄｎａのフラグメント並びにその製造法及び生物学的利用方法
CN104232676B (zh) 一种获得微环dna的亲本质粒及其应用
CN111718964A (zh) 用于修复dmd基因突变的核酸序列及系统
CN109486844B (zh) 一种肠毒素性大肠杆菌的特异性标记方法
WO2023108405A1 (fr) Vecteur recombiné, son procédé de construction et son utilisation
CN116262935A (zh) 重组载体及其构建方法和应用
WO2012151718A1 (fr) Promoteur de gène de myostatine de porc et ses applications
CN116286917A (zh) 重组载体及其构建方法和应用
Penewit et al. Recombineering in Staphylococcus aureus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21967541

Country of ref document: EP

Kind code of ref document: A1